Epstein-Barr virus (EBV) infection and its relevance in post-transplant lymphoproliferative diseases (PTLDs) is an increasing area of concern. PTLD can differ clinically from a mononucleosis-like syndrome to malignant lymphoma. The incidence varies between < 1 and > 20% depending on different risk factors and the kind of transplant. Despite several treatment regimens, including reduction of immunosuppression, antiviral drugs, adoptive immunotherapy and administration of anti-CD20 monoclonal antibodies, the mortality rate is still high. Novel therapeutic strategies for managing PTLD use pharmacological induction of the viral thymidine kinase gene in tumour cells, the target of antivirals based on nucleoside analogues, followed by treatment with ganciclovir. Further treatment modalities include the development of vaccines and targeting of the latent EBV episomes. Prevention of PTLD by pre-emptive therapy based on molecular monitoring of EBV load will represent the main aim to reduce occurrence. This review examines patents and literature for the treatment of EBV-associated lymphoproliferative diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543776.14.4.527 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic advances in chronic lymphocytic leukemia: A focus on molecular pathogenesis, targeted therapies, and supportive care.
Am J Health Syst Pharm
March 2025
Houston Methodist West Hospital, Houston, TX, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFClassification of NK-large granular lymphocytic leukemia by CD56 expression.
Oncologist
March 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China.
NK-large granular lymphocytic leukemia (NK-LGLL) is a rare chronic lymphoproliferative disorder and displays heterogeneity that remains insufficiently defined. CD56 plays a pivotal role in NK-cell maturation linked to cytotoxicity. However, whether CD56 might be associated with distinctive characteristics in NK-LGLL has not been determined.
View Article and Find Full Text PDFFDG PET Scan in Cutaneous Rosai-Dorfman-Destombes Disease.
Indian J Nucl Med
January 2025
Spect Lab Nuclear Medicine Services, Pune, Maharashtra, India.
Rosai-Dorfman-Destombes (RDD) disease is also called as sinus histiocytosis and is characterized by enlarged lymph nodes and previously called as non-Langerhans cell histiocytosis. Based on pathologic, molecular, and genetic features, RDD disease has been classified into sporadic noncutaneous (classical nodal, extranodal, neoplasia associated, and autoimmune associated), familial (H syndrome, autoimmune lymphoproliferative syndrome related, and familial NOS), and cutaneous subtypes. Cutaneous RDD disease is not associated with lymphadenopathy or visceral organ involvement.
View Article and Find Full Text PDFClinical Outcome of UCBT for Children with CAEBV: A Retrospective Analysis of a Single Center.
Transplant Cell Ther
March 2025
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. Electronic address:
Background: Chronic active Epstein-Barr virus (CAEBV) infection is a severe, life-threatening condition characterized by persistent Epstein-Barr virus (EBV) infection and the clonal expansion of infected T or NK cells, leading to systemic inflammation, organ damage, and complications such as hemophagocytic lymphohistiocytosis and lymphoma. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only effective treatment for eradicating EBV-infected cells; however, donor availability is limited. Umbilical cord blood stem cell transplantation (UCBT) is a promising alternative owing to its rapid availability and lower complication risk.
View Article and Find Full Text PDFModels for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity.
Leukemia
March 2025
Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf, Translational Research for Infectious Diseases and Oncology (TRIO), University Hospital Cologne, Cologne, Germany.
T-large granular lymphocytic leukemia (T-LGLL) is a chronic lymphoproliferative disorder characterized by clonal expansions of cytotoxic T-cells. It presents with cytopenias that are not explained by the typically low leukemic burden. Notably, T-LGLL is frequently accompanied by autoimmune disorders, particularly rheumatoid arthritis (RA).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!